Based on our preclinical research, ISC-hpNSC® has the potential to provide neurotrophic support and neuroregeneration to the affected tissues of the recipient brain. ISC-hpNSC® is the world’s first pluripotent stem cell based therapy for PD and if successful, it would represent a paradigm shift in the treatment of this devastating disease.
StemGenex Medical Group StemGenex Medical Group is committed to helping people achieve optimum health and better quality of life through the healing benefits of their own stem cells. StemGenex provides stem cell therapy options for individuals suffering with inflammatory and degenerative illnesses. Committed to the science and innovation of stem cell treatment, StemGenex sponsors five clinical outcome studies registered with the National Institutes of Health ("NIH") for Multiple Sclerosis, Parkinson's Disease
ISC-hpNSC® therapy is a genuine stem cell therapy trial conducted by international Stem Cell Corporation. It has a lot of potential of curing or at least halting the progression of PD. If someone is interested in finding the latest status of the trial, here is the link:
The bad news is that it will take 3 to 4 more years in becoming available in the market
StemGenex on the other hand is total fraud. They are using clinicaltrials.gov as their advertisement tool. The trial shown to be "Sponsored" by them on clinicaltrials.gov are actually charged from the patients. I had called them for enrollment in their trial. They told me that they are charging 15000 dollars for receiving the therapy.
Many patients have taken them to the court for false claims and their sham therapy
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Stem Cell therapy for PD
Encouraging Stem Cell Trial Results 
Aromatic-turmerone induces neural stem cell proliferation in vitro and in vivo 2014
